Literature DB >> 9305589

Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.

A J Munns1, J J De Voss, W D Hooper, R G Dickinson, E M Gillam.   

Abstract

The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3',4'-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes. Radiolabeled HPPH and CAT and unlabeled CAT were obtained from microsomal incubations and isolated by preparative HPLC. NADPH-dependent covalent binding was demonstrated in incubations of human liver microsomes with HPPH. When CAT was used as substrate, covalent adduct formation was independent of NADPH, was enhanced in the presence of systems generating reactive oxygen species, and was diminished under anaerobic conditions or in the presence of cytoprotective reducing agents. Fluorographic analysis showed that radiolabel derived from DPH and HPPH was selectively associated with proteins migrating with approximate relative molecular weights of 57-59 kDa and at the dye front (molecular weights < 23 kDa) on denaturing gels. Lower levels of radiolabel were distributed throughout the molecular weight range. In contrast, little selectivity was seen in covalent adducts formed from CAT. HPPH was shown to be a mechanism-based inactivator of P450, supporting the contention that a cytochrome P450 is one target of covalent binding. These results suggest that covalent binding of radiolabel derived from DPH in rat and human liver microsomes occurs via initial P450-dependent catechol formation followed by spontaneous oxidation to quinone and semiquinone derivatives that ultimately react with microsomal protein. Targets for covalent binding may include P450s, though the catechol appears to be sufficiently stable to migrate out of the P450 active site to form adducts with other proteins. In conclusion, we have demonstrated that DPH can be bioactivated in human liver to metabolites capable of covalently binding to proteins. The relationship of adduct formation to DPH-induced hypersensitivity reactions remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305589     DOI: 10.1021/tx9700836

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  8 in total

Review 1.  Reactive metabolites and adverse drug reactions: clinical considerations.

Authors:  Sandra R Knowles; Lori E Shapiro; Neil H Shear
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

Review 2.  Oxidative stress, unfolded protein response, and apoptosis in developmental toxicity.

Authors:  Allison Kupsco; Daniel Schlenk
Journal:  Int Rev Cell Mol Biol       Date:  2015-03-11       Impact factor: 6.813

Review 3.  Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; B K Park
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 4.  Drug-induced immunotoxicity.

Authors:  P M Dansette; E Bonierbale; C Minoletti; P H Beaune; D Pessayre; D Mansuy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Oct-Dec       Impact factor: 2.441

Review 5.  Herb-drug interactions: a literature review.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi Lui Ho; Sui Yung Chan; Paul Wan Sia Heng; Eli Chan; Wei Duan; Hwee Ling Koh; Shufeng Zhou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine.

Authors:  Robin E Pearce; Wei Lu; Yongqiang Wang; Jack P Uetrecht; Maria Almira Correia; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2008-05-07       Impact factor: 3.922

7.  Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects.

Authors:  Judy L Bolton; Tareisha Dunlap
Journal:  Chem Res Toxicol       Date:  2016-09-29       Impact factor: 3.739

8.  Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.

Authors:  Alison E Fohner; Allan E Rettie; Khanh K Thai; Dilrini K Ranatunga; Brian L Lawson; Vincent X Liu; Catherine A Schaefer
Journal:  Clin Transl Sci       Date:  2020-04-18       Impact factor: 4.689

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.